COVID-19 is a worldwide emergency since it has rapidly spread from China to almost all the countries worldwide. Italy has been one of the most affected countries after China. North Italian regions, such as Lombardia and Veneto, had an abnormally large number of cases. COVID-19 patients management requires availability of sufficiently large number of Intensive Care Units (ICUs) beds. Resources shortening is a critical issue when the number of COVID-19 severe cases are higher than the available resources. This is also the case at a regional scale. We analysed Italian data at regional level with the aim to: (i) support health and government decision-makers in gathering rapid and efficient decisions on increasing health structures capacities (in terms of ICU slots) and (ii) define a geographic model to plan emergency and future COVID-19 patients management using reallocating them among health structures. Finally, we retain that the here proposed model can be also used in other countries.

Type 1 Diabetes Mellitus (T1DM) is a chronic metabolic disease affecting millions of people worldwide. T1DM requires patients to continuously monitor their blood glucose levels. Due to pancreatic dysfunctions, patients use insulin injections to correct glucose values by synthetic insulin. Continuous Glucose Monitoring (CGM) is a system which includes an algorithm allowing to measure (and in some cases to predict) glucose levels at a frequent sampling time. This enable implementing advanced devices, including automated insulin pump delivery. Nevertheless, CGM still presents some limitations, including (i) the delay (time lag) in detecting change in glucose levels compared to the traditional blood glucose measurement, and (ii) the lack of a sufficient and acceptable time to accurately predict glucose values. We propose a framework based on a Gated Recurrent Unit (GRU) model to forecast both short- and long-term glucose values using heart rate (HR) and interstitial glucose (IG) values. The framework acquires HR and IG data and predicts glucose values with higher precision compared to state-of-the-art models. For training and testing the proposed framework, we used the OhioT1DM Dataset, which includes physiological data such as HR and IG values collected over an 8-week observation period. Additionally, we validated our framework using two other glucose datasets to ensure its generalizability across different HR and IG sampling frequencies. The proposed framework can be used to optimize the CGM system by incorporating patient HR measurements, thereby improving the prediction of short- and long-term glucose levels and reducing risks associated with conditions like hypoglycemia. Experimental tests were conducted using HR and IG data from the OhioT1DM Dataset, as well as from two additional T1DM patient datasets. We analyzed 6 patients from Ohio dataset while we validated the algorithm on 23 patients coming from two different university hospitals (6 from the University of Catanzaro medical hospital and 17 gathered from a validated study at IRCCS San Matteo Hospital in Pavia) for a total number of 29 patients. Our framework demonstrates an improvement in forecasting IG values in terms of RMSE and MAE for different choice of prediction horizons (PH). In the case of a PH of 5, 10, 20, 30, and 60 min, we reach an RMSE of 5.0, 9.38, 15.27, 20.48, and 34.16 respectively. The framework is freely available as an open-source, with an example dataset on a GitHub repository (see https://github.com/rafgia/attention_to_glycemia). Our framework offers a promising solution for improving glucose level prediction and management in T1DM patients. By leveraging a GRU model and incorporating HR and IG values, we achieve more precise glucose level forecasting compared to state-of-the-art models. This approach not only enhances the accuracy of glucose predictions but also mitigates the risks associated with hypoglycemia.

The Fractional Flow Reserve (FFR) and instantaneous wave-Free Ratio (iFR) have been proposed and clinically validated to measure the pressure gradient across coronary stenoses. They provide quantitative information on stenosis severity. Both are used in coronary revascularization procedures to measure intracoronary pressure giving quantitative information to evaluate coronary diseases during angiographic procedures. We designed and implemented a tool able to acquire and measure iFR and FFR supporting the physicians studying and treating patients in interventional cardiology laboratories. We designed an extensive case study to assess the performance of the tool in (i) acquiring pressure signals from blood pressure measurement systems; (ii) calculating FFR and iFR; and (iii) filtering out extra-beats signals during realtime signal analysis phases. The tool, named JLabChart, is available online. We tested it on two sets of data for a total of 600 cycles from 201 pressure measurements performed on 65 patients, from the Interventional Cardiology Unit of Magna Graecia University. The recognition of cardiac cycles and keypoint of the pressure curve was effective in $100\%$ of cases for proximal (aortic) pressure and in $99.2\%$ for distal pressure. The FFR calculated by JLabChart had an excellent correlation ($R_p=0.960$; $p<0.001$) with the FFR values obtained through the commercial systems. Similar results were obtained with iFR ($R_p=0.998$; $p<0.001$). Finally, the tool measurement results were compared with a commercial tool proving JLabChart’s efficiency with real cases. It was also compared with measurements performed on synthetic vessels and stenosis designed using the Comsol commercial tool. JLabChart is able to provide reliable measurements of FFR and iFR indexes used to support decisions on interventional procedures. It represents a valuable open source support system that can be used in an interventional cardiology laboratory.

The SARS-CoV-2 virus, which is a major threat to human health, has undergone many mutations during the replication process due to errors in the replication steps and modifications in the structure of viral proteins. The XBB variant was identified for the first time in Singapore in the fall of 2022. It was then detected in other countries, including the United States, Canada, and the United Kingdom. We study the impact of sequence changes on spike protein structure on the subvariants of XBB, with particular attention to the velocity of variant diffusion and virus activity with respect to its diffusion. We examine the structural and functional distinctions of the variants in three different conformations: (i) spike glycoprotein in complex with ACE2 (1-up state), (ii) spike glycoprotein (closed-1 state), and (iii) S protein (open-1 state). We also estimate the affinity binding between the spike protein and ACE2. The market binding affinity observed in specific variants raises questions about the efficacy of current vaccines in preparing the immune system for virus variant recognition. This work may be useful in devising strategies to manage the ongoing COVID-19 pandemic. To stay ahead of the virus evolution, further research and surveillance should be carried out to adjust public health measures accordingly.